Goldman Sachs Group Inc Compass Therapeutics, Inc. Transaction History
Goldman Sachs Group Inc
- $555 Billion
- Q1 2024
A detailed history of Goldman Sachs Group Inc transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 122,712 shares of CMPX stock, worth $130,074. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122,712
Previous 206,597
40.6%
Holding current value
$130,074
Previous $322,000
24.84%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding CMPX
# of Institutions
80Shares Held
94.2MCall Options Held
0Put Options Held
0-
Orbimed Advisors LLC San Diego, CA22.4MShares$23.7 Million1.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.1MShares$11.8 Million0.04% of portfolio
-
Janus Henderson Group PLC London, X06.49MShares$6.88 Million0.01% of portfolio
-
Blackstone Inc New York, NY6.19MShares$6.56 Million0.05% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$6.39 Million0.0% of portfolio
About Compass Therapeutics, Inc.
- Ticker CMPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 101,285,000
- Market Cap $107M
- Description
- Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...